Stockscreener 앱 받기
4.015
1.13%
0.045
전일 마감가:
$3.97
열려 있는:
$3.95
하루 거래량:
200.62K
Relative Volume:
0.47
시가총액:
$378.69M
수익:
$35.11M
순이익/손실:
$-79.20M
주가수익비율:
-0.9258
EPS:
-4.3367
순현금흐름:
$-88.62M
1주 성능:
-3.02%
1개월 성능:
-4.63%
6개월 성능:
+6.08%
1년 성능:
-0.62%
1일 변동 폭
$3.95
$4.17
1주일 범위
$3.95
$4.36
52주 변동 폭
$1.35
$4.83
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
명칭
X 4 Pharmaceuticals Inc
전화
857-529-8300
주소
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
4.015 | 374.45M | 35.11M | -79.20M | -88.62M | -4.3367 |
VRTX
Vertex Pharmaceuticals Inc
|
447.54 | 108.72B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
627.93 | 64.89B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
848.03 | 50.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
302.58 | 39.06B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
155.37 | 33.16B | 742.00K | -1.37B | -1.07B | -7.0731 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-09 | 개시 | Guggenheim | Buy |
| 2025-12-05 | 재개 | Stifel | Buy |
| 2023-12-12 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2023-08-30 | 재개 | B. Riley Securities | Buy |
| 2022-12-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-12-12 | 개시 | Piper Sandler | Overweight |
| 2019-12-23 | 개시 | Oppenheimer | Outperform |
| 2019-12-18 | 개시 | ROTH Capital | Buy |
| 2019-12-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-12-05 | 개시 | B. Riley FBR | Buy |
| 2019-06-07 | 개시 | Stifel | Buy |
| 2019-06-05 | 개시 | Cowen | Outperform |
모두보기
X 4 Pharmaceuticals Inc 주식(XFOR)의 최신 뉴스
FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY - TradingView
RIGEL (RIGL) CEO uses 2,424 shares for tax-withholding, retains large stake - Stock Titan
Baker funds tied to ACAD (ACAD) report RSU and stock option grants - Stock Titan
XFOR Initiated Coverage by Leerink Partners -- Rating Outperform - GuruFocus
Leerink initiates X4 Pharmaceuticals stock with outperform rating - Investing.com
Leerink Partners Initiates X4 Pharmaceuticals at Outperform With $12 Price Target - marketscreener.com
Layoff Tracker: Merck continues New Jersey cuts, laying off 88 in Rahway - BioSpace
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
FULL HOUSE RESORTS TO BREAK GROUND ON THE PERMANENT AMERICAN PLACE CASINO - Weekly Voice
New hires at rare-disease drugmaker get 160,000 stock options - Stock Titan
Fennec Pharmaceuticals (FENC) CMO receives 168-share grant, holds 21,015 - Stock Titan
Trump Is Being Sued For Rescheduling Marijuana By Doctors And A Pharmaceutical Company Who Are 'Aggrieved' By The Move - Marijuana Moment
Viking Therapeutics, Inc. (VKTX) Stock Price, News, Quote & History - Yahoo Finance
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
X4 Pharmaceuticals (XFOR) Gains 2.73% as Stock Tests Key Resistance LevelsRating Change - thelegaladvocate.com
Is MYGN Stock a Buy at 0.4x Sales? What Investors Should Weigh - TradingView
Recursion (NASDAQ: RXRX) director sells 40,000 shares in planned trade - Stock Titan
X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference - The Manila Times
XFOR Q1 2026 Earnings: EPS Beats Estimates Despite Continued Pre-Revenue Status; Stock DeclinesQuarterly Earnings Report - thelegaladvocate.com
Torrent Pharmaceuticals Ltd. Hits All-Time High of Rs 4,698.8 as Momentum Builds Across Timeframes - Markets Mojo
Phathom (PHAT) director James Topper receives 24,122 RSUs in equity grant - Stock Titan
Universe Pharmaceuticals (NASDAQ: UPC) CEO receives share grants under 2026 equity plan - Stock Titan
[Form 4] INOVIO PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
How The X4 Pharmaceuticals (XFOR) Story Is Shifting With Mavorixafor And New EU Progress - Yahoo Finance
Bears are Losing Control Over X4 Pharmaceuticals (XFOR), Here's Why It's a 'Buy' Now - sharewise.com
Can Encompass Health's Expansion Strategy Make It a Hold for Now? - TradingView
X4 Pharmaceuticals (XFOR) Q1 2026 Earnings: Why the Beat MattersDebt Analysis Report - The Legal Advocate
X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
[EFFECT] X4 Pharmaceuticals, Inc SEC Filing - Stock Titan
Perceptive group holds 7.3% of X4 Pharmaceuticals (NASDAQ: XFOR) with exercisable warrants - Stock Titan
This Insider Has Just Sold Shares In X4 Pharmaceuticals - simplywall.st
ANIP Valuation: Does 9.8x Forward P/E Offer Upside? - TradingView
Apellis (NASDAQ: APLS) director tenders shares for $41 cash plus CVR - Stock Titan
Biogen deal: Apellis (APLS) VP tenders 65,955 shares, options cancelled - Stock Titan
Apellis (NASDAQ: APLS) director cashes out shares and options in Biogen tender offer - Stock Titan
Apellis (APLS) R&D chief converts stock and options to cash and CVRs in Biogen merger - Stock Titan
[Form 4] Apellis Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Biogen buys Apellis (APLS) for $41 cash plus CVR per share - Stock Titan
Biogen to acquire Apellis (NASDAQ: APLS) for $41 per share plus CVR - Stock Titan
Biogen deal: Apellis (APLS) director’s shares and options cashed out - Stock Titan
Biogen buys Apellis (NASDAQ: APLS) at $41 per share plus CVR - Stock Titan
Apellis (NASDAQ: APLS) director fully cashes out in Biogen merger swap - Stock Titan
Here is Why X4 Pharmaceuticals (XFOR) is Among the Unrivaled Penny Stocks to Buy Now - Yahoo Finance
X4 Pharmaceuticals (XFOR) corrects director nominee and expands equity plan - Stock Titan
X4 Pharma CFO Kirske sells $72,820 in common stock - Investing.com
X4 Pharmaceuticals (XFOR) CFO sells shares to cover tax obligation - Stock Titan
[144] X4 Pharmaceuticals, Inc SEC Filing - Stock Titan
Shareholders at X4 Pharmaceuticals (NASDAQ: XFOR) approve equity plan - Stock Titan
5 Unrivaled Penny Stocks to Buy Now - Insider Monkey
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
XFOR (X4 Pharmaceuticals) beats Q1 2026 EPS estimates by 21.6 percent, shares climb 3 percent.Collaborative Trading Signals - newser.com
X 4 Pharmaceuticals Inc (XFOR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.41%
0.21%
자본화:
|
볼륨(24시간):